AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Translesion DNA synthesis (TLS) and homologous recombination (HR) cooperate during S-phase to safeguard replication forks integrity. Thus, the inhibition of TLS becomes a promising point of therapeutic intervention in HR-deficient cancers, where TLS impairment might trigger synthetic lethality (SL). The main limitation to test this hypothesis is the current lack of selective pharmacological inhibitors of TLS. Herein, we developed a miniaturized screening assay to identify inhibitors of PCNA ubiquitylation, a key post-translational modification required for efficient TLS activation. After screening a library of 627 kinase inhibitors, we found that targeting the pro-survival kinase AKT leads to strong impairment of PCNA ubiquitylation. Mechanistically, we found that AKT-mediated modulation of Proliferating Cell Nuclear Antigen (PCNA) ubiquitylation after UV requires the upstream activity of DNA PKcs, without affecting PCNA ubiquitylation levels in unperturbed cells. Moreover, we confirmed that persistent AKT inhibition blocks the recruitment of TLS polymerases to sites of DNA damage and impairs DNA replication forks processivity after UV irradiation, leading to increased DNA replication stress and cell death. Remarkably, when we compared the differential survival of HR-proficient vs HR-deficient cells, we found that the combination of UV irradiation and AKT inhibition leads to robust SL induction in HR-deficient cells. We link this phenotype to AKT ability to inhibit PCNA ubiquitylation, since the targeted knockdown of PCNA E3-ligase (RAD18) and a non-ubiquitylable (PCNA K164R) knock-in model recapitulate the observed SL induction. Collectively, this work identifies AKT as a novel regulator of PCNA ubiquitylation and provides the proof-of-concept of inhibiting TLS as a therapeutic approach to selectively kill HR-deficient cells submitted to replication stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such impairment in PCNA ubiquitination enhances the killing of cancer cells treated with cisplatin”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such a post-transcriptional modification of PCNA can also be inhibited by using AKT inhibitors.”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [121]
In the citing paper
“displaying an even more potent effect in homologous recombination-deficient cells [121]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115 · cited 1×
“In fact, even before the vast repertoire of AKT targets were identified, multiple groups independently demonstrated the central involvement of AKT in promoting cell survival [14].”
BackgroundThe DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 1×
“As DNA damage is an unceasing threat arising from both endogenous and exogenous sources [27], DNA repair pathways are unable to cope with every single DNA damage event in real time, in particular at sensitive points of the cell cycle such as S-phase [28].”
BackgroundAKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772 · cited 2×
“6), a direct causality between ubi-PCNA decrease and SL induction cannot to be claimed given the multiple roles of AKT in cell survival pathways [13].”
BackgroundRAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO
Hoege, C., Pfander, B., Moldovan, G.-L., Pyrowolakis, G., & Jentsch, S. (2002) · Nature · doi:10.1038/nature00991 · Cited by 2,198 · cited 1×
“Such mild UV-triggered sensitivity observed in mammalian cells in comparison with the extreme phenotype observed in yeast [1], along with the central housekeeping roles of PCNA in DNA replication [41, 42], discouraged the field from further exploring the therapeutic potential of targeting PCNA ubiquitylation.”
BackgroundThe activation of Akt/PKB signaling pathway and cell survival
Song, G., Ouyang, G., & Bao, S. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00337.x · Cited by 1,888 · cited 1×
“AKT has a wellestablished anti-apoptotic function, operating both directly, through the phosphorylation of relevant targets such as BAD and caspases, and indirectly, through the transcriptional modulation of pro-survival or pro-apoptotic genes such as IKK/NF-κB and MDM2/p53 [15].”
BackgroundPCNA, the Maestro of the Replication Fork
Moldovan, G.-L., Pfander, B., & Jentsch, S. (2007) · Cell · doi:10.1016/j.cell.2007.05.003 · Cited by 1,796 · cited 1×
“Such mild UV-triggered sensitivity observed in mammalian cells in comparison with the extreme phenotype observed in yeast [1], along with the central housekeeping roles of PCNA in DNA replication [41, 42], discouraged the field from further exploring the therapeutic potential of targeting PCNA ubiquitylation.”
BackgroundLord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086 · cited 1×
“Moreover, recent reports revealed that HR deficiency is a much more widely spread feature of human cancers than anticipated [23, 43], and therefore it is a niche of critical importance for drug discovery and for the design of novel therapeutic strategies.”
BackgroundPI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020 · cited 1×
“PI3K is involved in AKT activation in response to several physiological ligands [19], but was not directly linked to AKT activation after genotoxic stimuli.”
BackgroundUbiquitin-binding domains in Y-family polymerases regulate translesion synthesis.
Bienko, M., Green, C. M., Crosetto, N., Rudolf, F., Zapart, G., Coull, B., Kannouche, P., Wider, G., Peter, M., Lehmann, A. R., et al. (2005) · Science · doi:10.1126/science.1120615 · Cited by 712 · cited 1×
“Ubi-PCNA, along with the specialized ubiquitin-binding domains present in the Y-family of polymerases [6], are key players in translesion DNA synthesis (TLS) across damaged DNA templates [7].”
Background
Cited by
Taglialatela, A., Leuzzi, G., Sannino, V., Cuella-Martin, R., Huang, J.-W., Wu-Baer, F., Baer, R., Costanzo, V., & Ciccia, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.016 · Cited by 173
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
Huang, T.-T., Lampert, E. J., Coots, C., & Lee, J.-M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102021 · Cited by 159
“As such, a pan-AKT inhibitor (AKTi) C11 or a pan-PI3K inhibitor (PI3Ki) LY294002 blocks the recruitment of translesion synthesis polymerases at sites of DNA damage, thus hindering the progression of DNA replication forks after UV irradiation, leading to replication stress and cell death [24].”
BackgroundDNA-PKcs: A Multi-Faceted Player in DNA Damage Response
Yue, X., Bai, C., Xie, D., Ma, T., & Zhou, P.-K. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.607428 · Cited by 160
CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication
Mansilla, S. F., De La Vega, M. B., Calzetta, N. L., Siri, S. O., & Gottifredi, V. (2020) · Genes · doi:10.3390/genes11060593 · Cited by 114
Self-citationTargeting AKT/PKB to improve treatment outcomes for solid tumors
Iida, M., Harari, P. M., Wheeler, D. L., & Toulany, M. (2020) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2020.111690 · Cited by 84
Metadata
- Authors
- Villafañez, F., García, I. A., Carbajosa, S., Pansa, M. F., Mansilla, S., Llorens, M. C., Angiolini, V., Guantay, L., Jacobs, H., Madauss, K. P., Gloger, I., Gottifredi, V., Bocco, J. L., & Soria, G.
- Affiliations
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Fundación Instituto Leloir (AR)
- The Netherlands Cancer Institute (NL)
- GlaxoSmithKline (United States) (US)
- ORCID
- Venue
- Oncogene
- Published
- 2019-01-31
- Volume
- 38
- Issue
- 22
- Pages
- 4310-4324
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC6756059
- OpenAlex
- W2911296807
- Cited by
- 30
- References
- 54
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 8 · 2020: 8 · 2019: 5
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Greater South Information System
- Funders
- Ministry of Science, Technology and Productive Innovation, Argentina | National Agency for Science and Technology, Argentina | Fondo para la Investigación Científica y Tecnológica (PICT startup 2013-1553, PAE GSK 2014-0005, PAE-GSK 2014-0005)
- GlaxoSmithKline (PAE GSK 2014-0005)
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Instituto Nacional del Cáncer
- Ministry Of Health, Argentina | Instituto Nacional del Cáncer
- KWF Kankerbestrijding (10796/2016-2, 10032/2016-1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- AKT inhibition, translesion synthesis, synthetic lethality, homologous recombination deficiency, replication stress, DNA-PKcs, RAD18, UV irradiation, replication fork stability, kinase inhibitor screening
- MeSH terms
- Cell Line, DNA, DNA Damage, DNA-Directed DNA Polymerase, DNA Replication, Humans, Cell Death, Proliferating Cell Nuclear Antigen, Ubiquitin-Protein Ligases, HCT116 Cells, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Ubiquitination, HEK293 Cells, Homologous Recombination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress. https://app.cochat.ai/papers/10.1038/s41388-019-0724-7
- The paper
- Villafañez, F., García, I. A., Carbajosa, S., Pansa, M. F., Mansilla, S., Llorens, M. C., Angiolini, V., Guantay, L., Jacobs, H., Madauss, K. P., Gloger, I., Gottifredi, V., Bocco, J. L., & Soria, G. (2019). AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress. Oncogene. https://doi.org/10.1038/s41388-019-0724-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.